Nick Wykeman and Manuel Llobet from () caught up with Proactive Investors following the release of their interim results.
Allergy's continued to gain market share as it heads into a ‘pivotal’ twelve months.
Interim revenues rose by 4% to £42.2mln despite the pollen season being described as ‘abnormally weak’.
Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE